TrianglePUBLICATIONS · 37478390
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2023 Nov 20
- First author
- Dimopoulos MA
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Dimopoulos MA
- type
- Author
- name
- Opat S
- type
- Author
- name
- D'Sa S
- type
- Author
- name
- Jurczak W
- type
- Author
- name
- Lee HP
- type
- Author
- name
- Cull G
- type
- Author
- name
- Owen RG
- type
- Author
- name
- Marlton P
- type
- Author
- name
- Wahlin BE
- type
- Author
- name
- Garcia-Sanz R
- type
- Author
- name
- McCarthy H
- type
- Author
- name
- Mulligan S
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Dimopoulos MA
- type
- Author
- name
- Opat S
- type
- Author
- name
- D'Sa S
- type
- Author
- name
- Jurczak W
- type
- Author
- name
- Lee HP
- type
- Author
- name
- Cull G
- type
- Author
- name
- Owen RG
- type
- Author
- name
- Marlton P
- type
- Author
- name
- Wahlin BE
- type
- Author
- name
- Garcia-Sanz R
- type
- Author
- name
- McCarthy H
- type
- Author
- name
- Mulligan S
- type
- Author
- bibliography ids
- nci-bib-4fd53ec9a06c4f58d67e5bb6
- book metadata
- content sha256
- 0b1917c3ac126b1532ee1bcd170e8dec433f572c05d6c1f20cc3b5df57c5bb71
- document type
- citation
- dois
- 10.1200/JCO.22.02830
- electronic publication date
- display
- 2023 Jul 21
- precision
- day
- year
- 2023
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:37478390
- immutable id
- pubmed:37478390@0b1917c3ac126b1532ee1bcd170e8dec433f572c05d6c1f20cc3b5df57c5bb71
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 33
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 5099-5106
- volume
- 41
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 37478390
- provenance
- batch id
- 5329a5d0877ee70ecd11
- provider
- NCBI PubMed ESummary
- record sha256
- 41ba4b9e6fde3b659b1ea94c9c7b84e5e7eed3a5b5a75568d17958be7c9032a8
- response sha256
- bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
- retrieved at
- 2026-09-09T23:48:15.763286+00:00
- publication date
- display
- 2023 Nov 20
- precision
- day
- year
- 2023
- publication types
- Clinical Trial, Phase III
- Randomized Controlled Trial
- Journal Article
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Preserved source evidence · Independent clinical review pending · Not medical advice